drugset / Trial / NCT07123727
A Study to Examine Anktiva for the Treatment of COVID-19.
NaSingle-groupOpen-labelTreatment
Summary
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
Timeline
- Start
- 2025-09-04
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-803 | Protein / enzyme biologic | 600 ug | Subcutaneous |